Remove 2029 Remove Biosimilars Remove Drug Development
article thumbnail

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

million by 2029. percent between 2022 and 2029. Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

article thumbnail

The Sun Has Started to Set on the Rare Pediatric Disease Priority Review Voucher Program – But It Can Still be Saved

FDA Law Blog: Biosimilars

Earlier in the week, it was reported that there was a bipartisan agreement on a bill that would have funded the government and extended the first sunset date for the rare pediatric disease priority review voucher program for nearly 5 years, until September 30, 2029.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog: Biosimilars

It is extremely difficult, if not impossible, to do the long-term planning and substantial fundraising required for drug development without knowing whether such an important and valuable incentive will be there. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Industry reactions have been mixed. Similarly, Williams says such crises may even be seen as opportunities in the rare disease space.